PARIS–(BUSINESS WIRE)–Regulatory Information:
Ikonisys SA (Euronext Progress Paris: ALIKO), an organization specializing within the early and correct detection of most cancers by means of totally automated options for medical laboratories, is happy to announce that its fully-owned firm Hospitex Worldwide has efficiently gained the general public tender for the in-service provide of diagnostic techniques to the U.O.C. Pathological Anatomy Unit in Enna, Italy.
This tender follows the launch of an open process for the in-service provide of diagnostic techniques meant for the Public Well being Laboratory Unit and the U.O.C. Umberto 1st Pathological Anatomy Unit in Enna.
The contract consists of the total in-service provide of its CYTOfast system with a complete worth nearing €400.000 primarily based on value/high quality parameters.
Throughout a public session, the fee reviewed administrative and technical documentation to evaluate compliance from collaborating firms. This new milestone as soon as once more highlights Hospitex’s ongoing dedication to delivering modern and environment friendly options for early most cancers analysis.
Francesco Trisolini, COO of Ikonisys and CEO of Hospitex, acknowledged: This achievement is a big step for Hospitex Worldwide, reaffirming our dedication to bettering diagnostic accuracy and streamlining the diagnostic course of. We’re excited to proceed combining our experience and positioning our firms as leaders in most cancers diagnostics.
This Public Tender represents a chance for Ikonisys Group to place on main initiatives.
About Hospitex Worldwide
Hospitex Worldwide is the world main firm for cytology standardized monolayer preparations. With CYTOfast it has re-invented the cytological diagnostics. Hospitex gives a full vary of built-in options aimed toward streamlining diagnostic processes in cytology. The worldwide scarcity of experience in pathology requires instruments and applied sciences that allow diagnostic security, effectivity and capability constructing. On this space, Hospitex is acknowledged because the precision diagnostics participant in cytology.
For extra info: https://www.hospitex.com/en/
About Ikonisys
Ikonisys SA is a cell-based diagnostics firm primarily based in Paris (France), New Haven (Connecticut, USA) and Milan (Italy) specialised within the early and correct detection of most cancers. The corporate develops, produces and markets the proprietary Ikoniscope20 ® and Ikoniscope20max ® platforms, fully-automated options designed to ship correct and dependable detection and evaluation of uncommon and really uncommon cells. Ikonisys has obtained FDA clearance for a number of automated diagnostic functions, that are additionally marketed in Europe beneath CE certification. Via its breakthrough fluorescence microscopy platform, the corporate continues to develop a stream of latest checks, together with liquid biopsy checks primarily based on Circulating Tumor Cells (CTC).
For additional info, please go to www.ikonisys-finance.com
Disclaimer
This press launch accommodates forward-looking statements concerning the Firm’s prospects and improvement. These statements are generally recognized by means of the longer term tense, the conditional tense and forward-looking phrases reminiscent of “believe”, “aim to”, “expect”, “intend”, “estimate”, “believe”, “should”, “could”, “would” or “will” or, the place acceptable, the destructive of those phrases or some other comparable variants or expressions. This info just isn’t historic knowledge and shouldn’t be construed as a assure that the details and knowledge set forth will happen. This info relies on knowledge, assumptions and estimates thought of affordable by the Firm. It’s topic to vary or modification attributable to uncertainties referring to the financial, monetary, aggressive and regulatory setting. This info accommodates knowledge referring to the Firm’s intentions, estimates and targets regarding, particularly, the market, technique, development, outcomes, monetary state of affairs and money move of the Firm. The forward-looking info contained on this press launch is made solely as of the date of this press launch. The Firm doesn’t undertake to replace any forward-looking info contained on this press launch, besides as required by relevant legislation or regulation. The Firm operates in a aggressive and quickly altering setting and due to this fact can’t anticipate all the dangers, uncertainties or different components that will have an effect on its enterprise, their potential affect on its enterprise or the extent to which the materialization of anybody danger or mixture of dangers may trigger outcomes to vary materially from these expressed in any forward-looking info, it being recalled that none of this forward-looking info constitutes a assure of precise outcomes.
View supply model on businesswire.com: https://www.businesswire.com/information/house/20241009362220/en/
Ikonisys
Alessandro Mauri
CFO
buyers@ikonisys.com
NewCap
Louis-Victor Delouvrier/Aurélie Manavarere
Investor Relations
ikonisys@newcap.eu
Tel.: +33 (0)1 44 71 94 94
NewCap
Nicolas Merigeau
Media Relations
ikonisys@newcap.eu
Tel.: +33 (0)1 44 71 94 98
Supply: Ikonisys
